CD274 and non-small cell lung carcinoma: Moreover, immunotherapy, specifically immune checkpoint inhibitors targeting the PD-1/PD-L1 axis, has surfaced as an encouraging treatment avenue for NSCLC, conferring significant survival improvements for some patients [6].